MAIA Biotechnology Inc. (MAIA)

MAIA Biotechnology Inc. (MAIA) is a Biotechnology company in the Healthcare sector listed on the AMEX.

As of Oct 23, 2026: market cap $71.6M; returns 1 day +1.8%, 1 week +4.5%, 1 year -21.2%.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted immunotherapies for cancer. Their lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) patients with telomerase-positive cancer cells.

Groups MAIA belongs to

• Clinical Stage Biotech
• Biotechnology
• Oncology
• Healthcare
• Biopharmaceutical
• Cancer Therapeutics
• Clinical Stage
• Immunotherapy
• Life Sciences
• Drug Discovery

MAIA financial model: income statement, cash flow and balance sheet